The first of two pre-clinical studies investigating mechanistic aspects of chemotherapy induced angiogenesis showed for the first time that nab-paclitaxel, as well as standard chemotherapies like solvent-based paclitaxel (Taxol(R)) and doxorubicin, can trigger reactionary angiogenesis with concomitant increased secretion from tumors of angiogenic factors, such as VEGF. This 'reactionary angiogenesis' provides a strong mechanistic rationale for combination of nab-paclitaxel therapy with the VEGF inhibitor drugs, such as bevacizumab, to enhance the antitumor response. (Abstract #4636; Investigation of Chemotherapy-induced Tumor Angiogenesis: Rationale for Combination of nab-paclitaxel with Anti-VEGF Therapy).
The second pre-clinical study, which investigated tumor regression and metastasis, found that the combination of nab-paclitaxel with bevacizumab in breast cancer tumor models showed significantly enhanced anti-tumor response with a significantly reduced frequency of metastasis to the lymph nodes and lungs as compared to single agent therapy. (Abstract #2201; The Role of VEGF in Chemoprotection and Tumor Metastasis: Rationale for Combination of nab-paclitaxel and bevacizumab). Both studies demonstrate the potential of nab-paclitaxel in combination with bevacizumab as an effective antitumor agent.
Abraxis continues to explore the rol e of nab-technology for targeting SPARC and other biological pathways, as well as for the development of new therapeutic candidates such as nab-docetaxel (ABI-008), the mTOR inhibitor nab-rapamycin (ABI-009), and the HSP90 inhibitor nab-17-AAG (ABI 010), among others.
About nab(TM) Technology Platform
Developed by Abraxis BioScience, nanoparticle albumin-bound (nab(TM)) tumor-targeting technology harnesses the unique natural properties of the human protein albumin, to transport and deliver therapeutic agents to the site of disease. The binding of albumin to the anticancer agent creates nanometer-sized particles, which are approximately 1/100th the size of a single red blood cell. These nab particles are readily incorporated into the body's own transport processes and are able to exploit the tumors' attraction to albumin, enabling the delivery of higher concentrations of the active drug to the target site. This may lead to an increase in the drug's antitumor effect and the potential for an effective response. In addition, nab technology offers the ability to improve a drug's solubility by avoiding the need for toxic chemicals, such as solvents, in the administration process, thus potentially improving safety through the elimination of solvent-related side effects.
Abraxis BioScience received approval from the U.S. Food and Drug Administration for ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease in 2005, its first product developed using the nab technology. Studies are ongoing to evaluate several other therapeutic candidates that employ the nab technology including nab-docetaxel (ABI-008), nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010), among others.
The U.S. Food and Drug Administration approved ABRAXANE(R) for Injectable Suspension (paclitaxe l protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. For the full prescribing information for ABRAXANE(R), please visit www.abraxane.com.
ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP.
About Abraxis BioScience, Inc.
Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on The Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securitie s Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the timing and scope of clinical studies and trials for nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010). Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the fact that results from pre-clinical studies may not be predictive of results to be obtained in other pre-clinical studies or future clinical trials, delays in commencement and completion of clinical trials, including slower than anticipated patient enrollment and adverse events occurring during the clinical trials, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, the ability to successfully manufacture products in a time-sensitive and cost effective manner, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties. Additional relevant information concerning risks can be found in Abraxis BioScience's Form 10-K for the year ended December 31, 2006 and other documents it has filed with the Securities and Exchange Commission.
The information contained in this press release is as of the date of this release. Abraxis assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.
Avastin(R) (bevacizumab) is a registered trademark of Genentech Inc.
Taxol(R) (paclitaxel) is a registered trademark of Bristol-Myers Squibb Co mpany.
Abraxis BioScience, Inc.
Investors and Media:
Christine Cassiano, 310-405-7417
Claire Campbell, 908-393-8238